| Issue Date | Title | Author(s) |
| 2016 | Efficacy and safety of fenofibrate as an add-on in patients with elevated triglyceride despite receiving statin treatment | Zhao, Shuiping; Wang, Fang; Dai, Yangyang; Lin, Ling; Tong, Qiguang; Liao, Yuhua; Yin, Yuehui; Wang, Guang; Yan, Yafei; Li, Xiaodong; Wang, Daowen; Wei, Ping; Cheng, Xingbo; Xie, Qiang; Sun, Yuemin; Fu, Guosheng; Huang, Hongman; Dong, Yugang; Liu, Jianxiong; Yan, Jianling; Yan, Li; Cui, Shiwei; Liu, Xuebo; Li, Zhaoping; Chen, Hong; Hu, Taohong; Gong, Hui |
| 12-Dec-2022 | Pulmonary Artery Denervation for Pulmonary Arterial Hypertension A Sham-Controlled Randomized PADN-CFDA Trial | Zhang, Hang; Wei, Yongyue; Zhang, Caojin; Yang, Zhenwen; Kan, Jing; Gu, Heping; Fan, Fenling; Gu, Hong; Wang, Qiguang; Xie, Dujiang; Zhang, Gangcheng; Guo, Xiaomei; Yin, Yuehui; Jin, Bowen; Zhou, Hongmei; Yang, Ziyang; Wang, Zhouming; Xin, Yu; Zhang, Chen; Meng, Lili; Wang, Xiaoyu; Sun, Jingping; Zhao, Chunxia; Zhang, Juan; Yan, Xiaoyan; Chen, Feng; Yao, Cheng; Stone, Gregg W.; Chen, Shao-Liang |
| Aug-2022 | Rationale and Design of Sympathetic Mapping/Ablation of Renal Nerves Trial (SMART) for the Treatment of Hypertension: a Prospective, Multicenter, Single-Blind, Randomized and Sham Procedure-Controlled Study | Wang, Jie; Sun, Ningling; Ge, Junbo; Jiang, Hong; Yin, Yuehui; Chen, Minglong; Wang, Yue; Yao, Chen; Yan, Xiaoyan; Sobotka, Paul A.; Huo, Yong |
| Oct-2023 | A sham-controlled randomised trial of pulmonary artery denervation for Group 1 pulmonary arterial hypertension: one-year outcomes of the PADN-CFDA trial | Kan, Jing; Zhang, Hang; Xie, Dujiang; Wei, Yongyue; Zhang, Juan; Zhang, Caojin; Yang, Zhenwen; Gu, Heping; Fan, Fenling; Gu, Hong; Wang, Qiguang; Zhang, Gangcheng; Guo, Xiaomei; Yin, Yuehui; Wang, Xiang; Jin, Bowen; Zhou, Hongmei; Yang, Ziyang; Wang, Zhouming; Xin, Yu; Zhang, Chen; Meng, Lili; Wang, Xiaoyu; Zhao, Chunxia; Yan, Xiaoyan; Chen, Feng; Yao, Cheng; Stone, Gregg W.; Chen, Shao-Liang |
| Oct-2023 | A sham-controlled randomised trial of pulmonary artery denervation for Group 1 pulmonary arterial hypertension: one-year outcomes of the PADN-CFDA trial | Kan, Jing; Zhang, Hang; Xie, Dujiang; Wei, Yongyue; Zhang, Juan; Zhang, Caojin; Yang, Zhenwen; Gu, Heping; Fan, Fenling; Gu, Hong; Wang, Qiguang; Zhang, Gangcheng; Guo, Xiaomei; Yin, Yuehui; Wang, Xiang; Jin, Bowen; Zhou, Hongmei; Yang, Ziyang; Wang, Zhouming; Xin, Yu; Zhang, Chen; Meng, Lili; Wang, Xiaoyu; Zhao, Chunxia; Yan, Xiaoyan; Chen, Feng; Yao, Cheng; Stone, Gregg W.; Chen, Shao-Liang |
| Aug-2023 | Treatment effects of pulmonary artery denervation for pulmonary arterial hypertension stratified by REVEAL risk score: Results from PADN-CFDA trial | Zhang, Juan; Kan, Jing; Wei, Yongyue; Zhang, Caojin; Yang, Zhenwen; Gu, Heping; Fan, Fenling; Gu, Hong; Wang, Qiguang; Xie, Dujiang; Zhang, Gangcheng; Guo, Xiaomei; Yin, Yuehui; Jin, Bowen; Zhou, Hongmei; Yang, Ziyang; Wang, Zhouming; Xin, Yu; Zhang, Chen; Meng, Lili; Wang, Xiaoyu; Zhao, Chunxia; Zhang, Hang; Yan, Xiaoyan; Chen, Feng; Yao, Cheng; Benza, Raymond L.; Stone, Gregg W.; Chen, Shao-Liang |
